PALISADE BIO, INC. Long-term Debt, Gross
PALISADE BIO, INC. (PALI) had Long-term Debt, Gross of $87.00 thousand as of 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentCarryingAmount · last filed 2022-03-17
- 2021-12-31: Long-term Debt, Gross $87.00K.
- 2021-09-30: Long-term Debt, Gross $573.00K.
- 2021-06-30: Long-term Debt, Gross $1.16M.
- 2020-12-31: Long-term Debt, Gross $2.72M.
| Period end | Long-term Debt, Gross |
|---|---|
| 2021-12-31 | $87.00K 10-K · filed 2022-03-17 |
| 2021-09-30 | $573.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.16M 10-Q · filed 2021-08-23 |
| 2020-12-31 | $2.72M 10-K · filed 2022-03-17 |
| 2013-03-31 | $8.00M 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |